आईएसएसएन: 2168-9784
Piérard GE, Hermanns-Lê T, Piérard-Franchimont C, Piérard SL
Objective: Treatment options for moderate to severe skin psoriasis have considerably progressed over the past decades with the widespread use of targeted biologicals including Tumor Necrosis Factor antagonists (TNFa).
Objective and reliable analytical assessments of the disease course and the treatment efficacy are eagerly awaited.
Methods: To disclose initial therapeutic effects of the adalimumab TNFa in a group of 13 psoriatic patients. The analytical observations relied on two in vivo real-time non-invasive methods, namely Reflectance Confocal Microscopy (RCM) and skin capacitance mapping (SCM). The L* colorimetric assessment of pictures was used for analytical assessments.